Fmr LLC trimmed its stake in shares of Radius Health Inc (NASDAQ:RDUS) by 15.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 989,856 shares of the biopharmaceutical company’s stock after selling 180,553 shares during the quarter. Fmr LLC owned about 2.17% of Radius Health worth $16,323,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of RDUS. Bank of Montreal Can lifted its position in Radius Health by 231.3% during the 4th quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,078 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Radius Health in the 3rd quarter valued at approximately $110,000. Pacer Advisors Inc. acquired a new stake in shares of Radius Health in the 3rd quarter valued at approximately $186,000. Virtu Financial LLC acquired a new stake in shares of Radius Health in the 4th quarter valued at approximately $205,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Radius Health in the 3rd quarter valued at approximately $208,000.
Several analysts have recently commented on the company. HC Wainwright assumed coverage on Radius Health in a report on Thursday, February 14th. They issued a “neutral” rating and a $22.00 price target for the company. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, January 22nd. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Thursday, January 17th. Finally, ValuEngine cut Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $39.43.
RDUS opened at $18.92 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 5.79 and a current ratio of 5.92. Radius Health Inc has a 12 month low of $12.81 and a 12 month high of $37.66.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/4244969/fmr-llc-sells-180553-shares-of-radius-health-inc-rdus.html.
Radius Health Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.